News and Events
The University of Minnesota College of Pharmacy and Kailos Genetics, a HudsonAlpha Institute for Biotechnology resident company, have established a pharmacogenetic testing and internship program.
Associate professor Adam Duerfeldt, PhD, joined the College of Pharmacy’s Department of Medicinal Chemistry on Dec. 28, 2020.
Barbara Brandt, PhD, and Mark Schneiderhan, PharmD, BCCP, have been inducted into the Academies of Excellence.
Paul Ranelli, PhD, MS, is the 2020 recipient of the Lifetime Achievement Award from the Pharmacy Section of the American Public Health Association.
Also recognized at the awards event were former University of Minnesota pharmacy leadership resident, Vibhuti Arya, who received the Sustained Contributor Award, and alum Chamika Hawkins-Taylor who received the Early Career Award.
A virtual award ceremony was held on Oct. 25, 2020.
Karen Bastianelli, BSPharm, PharmD, BCACP has been named an American Pharmacists Association (APhA) 2021 fellow. She is recognized by APhA for education and support to early-career pharmacists and directly giving back to her community.
According to the U.S. Centers for Disease and Prevention (CDC), influenza (flu) viruses are most common during the fall and winter. The CDC has indicated it believes it’s likely that flu viruses and the virus that causes COVID-19 will both be spreading in the fall and winter. Ann Philbrick with the University of Minnesota talks about the flu vaccine and the health benefits of getting routine immunizations.
UMN College of Pharmacy and Consortium Partners Receive $1M Grant to Provide Substance Use Prevention, Treatment and Recovery Services on the Bois Forte Reservation
The University of Minnesota College of Pharmacy and its consortium partners have received a $1 million Health Resources & Services Administration (HRSA) grant for substance use prevention, intervention, recovery and harm reduction for the Bois Forte Nation.
University of Minnesota startup RoundtableRx to reroute unused medications away from disposal to help those in need
Over the past few months, a number of drugs have been under investigation to treat COVID-19 without well-established safety or data to support these claims. However, some of these unproven therapies may have underlying genetic reasons for not being effective and resulting in fatal adverse effects as found with hydroxychloroquine.